Informa (LSE: INF.L), the International Exhibitions, Events, Information Services and Advanced Learning Group, today announces further investment in developing its Open Access (“OA”) publishing capabilities through the addition of F1000 Research Ltd. by Taylor & Francis.
|
Stephen A. Carter, Group Chief Executive, Informa PLC, said: “Under the leadership of Annie Callanan in Taylor & Francis, we are deepening our Open Access and also now our Open Research capabilities.” He added: “F1000 Research is a leader in its field, committed to the further development of independent, high quality Open Science and Research. We are delighted to welcome Rebecca Lawrence and the team from F1000 Research, and are committed to the further technology and capability development that Open Research needs.” Vitek Tracz, Founder, F1000, said: “F1000 Research is a pioneer of quality and independence, with a deep commitment to Open Science and Research. Taylor & Francis is a great fit culturally and its commitment to further investment and development is timely, given the likely acceleration of Open services.” |
F1000 Research Ltd. offers fully managed, open research publishing services directly to research funders, learned societies and institutions, including the Wellcome Trust and the Bill & Melinda Gates Foundation.
Additionally, F1000Research is the leading independent open research publishing platform for scientists and academic scholars. Its innovative platform enables the rapid publication of academic research, whilst maintaining quality and transparency, and providing authors with greater autonomy through the process.
The addition of F1000 Research complements and extends Taylor & Francis’s programme of investment to expand our presence and capabilities within the increasingly important OA publishing arena. It follows the addition of leading independent OA journal publisher, Dove Medical Press, in 2017 and ongoing internal investment in developing our range of OA publications and services, with more than 300 OA journals now published across our total journal portfolio of over 2,700 titles.
No financial details of the transaction were disclosed.